Oncogenic pathways and the electron transport chain: a dangeROS liaison
Driver mutations in oncogenic pathways, rewiring of cellular metabolism and altered ROS
homoeostasis are intimately connected hallmarks of cancer. Electrons derived from different …
homoeostasis are intimately connected hallmarks of cancer. Electrons derived from different …
Biomarkers in breast cancer: an old story with a new end
L Neves Rebello Alves, D Dummer Meira… - Genes, 2023 - mdpi.com
Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease
and the leading cause of cancer mortality in women. Advances in molecular technologies …
and the leading cause of cancer mortality in women. Advances in molecular technologies …
[HTML][HTML] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final …
Background Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …
[HTML][HTML] Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients …
Background Alpelisib (α-selective phosphatidylinositol 3-kinase inhibitor) plus fulvestrant is
approved in multiple countries for men and postmenopausal women with PIK3CA-mutated …
approved in multiple countries for men and postmenopausal women with PIK3CA-mutated …
PIK3CA-mutations in breast cancer
K Reinhardt, K Stückrath, C Hartung, S Kaufhold… - Breast Cancer Research …, 2022 - Springer
Abstract Purpose Phosphatidylinositide-3-kinase (PI3K) regulates proliferation and
apoptosis; somatic PIK3CA-mutations may activate these processes. Aim of this study was to …
apoptosis; somatic PIK3CA-mutations may activate these processes. Aim of this study was to …
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
L Chen, L Yang, L Yao, XY Kuang, WJ Zuo, S Li… - Nature …, 2018 - nature.com
Deregulation of the phosphoinositide 3-kinase (PI3K) pathway contributes to the
development and progression of tumors. Here, we determine that somatic mutations in …
development and progression of tumors. Here, we determine that somatic mutations in …
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of …
A Bardia, J Cortés, FC Bidard, P Neven… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with
manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with …
manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with …
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study
I Alborelli, D Generali, P Jermann, MR Cappelletti… - Cell death & …, 2019 - nature.com
Pre-symptomatic screening of genetic alterations might help identify subpopulations of
individuals that could enter into early access prevention programs. Since liquid biopsy is …
individuals that could enter into early access prevention programs. Since liquid biopsy is …
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the …
N Turner, RA Dent, J O'Shaughnessy, SB Kim… - Breast cancer research …, 2022 - Springer
Abstract Purpose PI3K/AKT pathway alterations are frequent in hormone receptor-positive
(HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib–paclitaxel in PI3K …
(HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib–paclitaxel in PI3K …
Management strategies for hyperglycemia associated with the α-selective PI3K inhibitor alpelisib for the treatment of breast cancer
T Tankova, E Senkus, M Beloyartseva, S Borštnar… - Cancers, 2022 - mdpi.com
Simple Summary Alpelisib is a drug used to treat breast cancer that has certain
characteristics (hormone receptor-positive (HR+), human epidermal growth receptor 2 …
characteristics (hormone receptor-positive (HR+), human epidermal growth receptor 2 …